TP-252

DB17912ExperimentalSmall molecule

TP-252 consists of magnesium L-lysinate bis-eicosapentaenoate, an ionizable salt of eicosapentaenoic acid (EPA), currently being investigated to treat familial adenomatous polyposis.

Formula / weight: C₅₂H₈₆MgN₄O₈ · 919.585 g/mol (avg)
Also known as: Magnesium bislysinate biseicosapentaenoate · Magnesium lysinate bis eicosapentaenoate · Magnesium, bis(l-lysinato-.kappa.n2,.kappa.o1)-, (t-4)-, (5z,8z,11z,14z,17z)-5,8,11,14,17-eicosapentaenoate (1:2)
Code names: TP-252

Resolves to

Compound

UNIIQDG62BO0C2CAS1841444-50-5

Structure

InChIKeyCRXRROKIRDSTAH-ZUDQWMAJSA-LSMILES

[Mg++].NCCCC[C@H](N)C([O-])=O.NCCCC[C@H](N)C([O-])=O.CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O.CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O

What you can answer from here — as of March 06, 2025

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of TP-252, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account